For example, TEX-mediated delivery of IMV-001 (an antisense oligonucleotide against the transmembrane receptor, IGF1R) to patients with recurrent malignant glioma was more effective than other delivery methods due as it was associated with an increased number of tumor-infiltrating lymphocytes and enhanced anti-tumor immunity (57, 58). The gene discussed is NRP1; the disease is neoplasm.